home / stock / bcac / bcac quote
Last: | $22.71 |
---|---|
Change Percent: | 114.65% |
Open: | $10.07 |
Close: | $10.58 |
High: | $27.74 |
Low: | $9.94 |
Volume: | 540,270 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$22.71 | $10.07 | $10.58 | $27.74 | $9.94 | 540,270 | 07-29-2022 |
$10.08 | $10.58 | $10.58 | $10.78 | $9.94 | 17,608 | 07-28-2022 |
$10.25 | $9.82 | $9.82 | $10.5 | $9.75 | 31,332 | 07-26-2022 |
$9.95 | $9.82 | $9.95 | $10.2 | $9.68 | 16,865 | 07-25-2022 |
$10.2001 | $10.2 | $10.2001 | $10.21 | $10.2 | 126,183 | 07-19-2022 |
$10.2 | $10.2 | $10.2 | $10.205 | $10.18 | 187,516 | 07-18-2022 |
$10.19 | $10.1701 | $10.19 | $10.19 | $10.17 | 36,714 | 07-15-2022 |
$10.18 | $10.18 | $10.18 | $10.18 | $10.17 | 54,519 | 07-14-2022 |
$10.17 | $10.17 | $10.17 | $10.17 | $10.165 | 16,692 | 07-13-2022 |
$10.17 | $10.18 | $10.17 | $10.18 | $10.16 | 43,583 | 07-12-2022 |
$10.17 | $10.17 | $10.17 | $10.17 | $10.17 | 853 | 07-11-2022 |
$10.17 | $10.17 | $10.17 | $10.175 | $10.17 | 2,296 | 07-08-2022 |
$10.17 | $10.17 | $10.17 | $10.175 | $10.17 | 46,243 | 07-07-2022 |
$10.17 | $10.165 | $10.17 | $10.17 | $10.165 | 5,291 | 07-06-2022 |
$10.165 | $10.165 | $10.165 | $10.165 | $10.165 | 415 | 07-05-2022 |
$10.16 | $10.165 | $10.16 | $10.165 | $10.16 | 1,353 | 07-04-2022 |
$10.16 | $10.165 | $10.16 | $10.165 | $10.16 | 1,353 | 07-01-2022 |
$10.16 | $10.16 | $10.16 | $10.16 | $10.16 | 191 | 06-30-2022 |
$10.16 | $10.16 | $10.16 | $10.16 | $10.16 | 3,104 | 06-29-2022 |
$10.17 | $10.17 | $10.17 | $10.17 | $10.17 | 1,599 | 06-28-2022 |
News, Short Squeeze, Breakout and More Instantly...
Bison Capital Acquisition Corp. Company Name:
BCAC Stock Symbol:
NASDAQ Market:
SAN CARLOS, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (“Apexigen”), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced that Apexigen’s Manageme...
SAN CARLOS, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (“Apexigen”), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the appointment of William Duke...
- Data from the Parker Institute for Cancer Immunotherapy and Cancer Research Institute multi-center Phase 2 PRINCE trial demonstrated that novel circulating and tumor biomarkers may be predictive of overall survival - - Identified distinct immune responses and biomarkers in...